118 related articles for article (PubMed ID: 36680930)
41. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
42. Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
de Jong JJ; Valderrama BP; Perera J; Juanpere N; Cejas P; Long H; Albà MM; Gibb EA; Bellmunt J
Br J Cancer; 2022 Jul; 127(2):313-320. PubMed ID: 35449454
[TBL] [Abstract][Full Text] [Related]
43. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW
PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113
[TBL] [Abstract][Full Text] [Related]
44. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Zhu J; Lu Z; Ke M; Cai X
Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
[TBL] [Abstract][Full Text] [Related]
45. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
46. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
[TBL] [Abstract][Full Text] [Related]
47. Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.
Ying Y; Wang Z; Tan Y; Cao H; Gao H; Zhang Z; Zeng S; Xu C
Transl Androl Urol; 2023 Feb; 12(2):176-186. PubMed ID: 36915888
[TBL] [Abstract][Full Text] [Related]
48. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
49. Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.
Papadopoulou K; Koliou GA; Tsimiliotis D; Kotoula V; Foukas P; Goussia A; Tsiatas M; Visvikis A; Chatzopoulos K; Nifora M; Charchanti A; Koumarianou A; Christodoulou C; Pectasides D; Psyrri A; Fostira F; Fountzilas G; Samantas E
Urol Oncol; 2022 Dec; 40(12):538.e15-538.e24. PubMed ID: 36041976
[TBL] [Abstract][Full Text] [Related]
50. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
51. Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.
Arslan AI; Karabağ S; Akgül M
Indian J Pathol Microbiol; 2022; 65(3):604-609. PubMed ID: 35900488
[TBL] [Abstract][Full Text] [Related]
52. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
[TBL] [Abstract][Full Text] [Related]
53. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
54. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
Weyerer V; Weisser R; Moskalev EA; Haller F; Stoehr R; Eckstein M; Zinnall U; Gaisa NT; Compérat E; Perren A; Keck B; Allory Y; Kristiansen G; Wullich B; Agaimy A; Hartmann A; Bertz S
Histopathology; 2019 Dec; 75(6):865-875. PubMed ID: 31348552
[TBL] [Abstract][Full Text] [Related]
55. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
56. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
57. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
Yang F; Zhou Q; Meng L; Xing N
Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
[TBL] [Abstract][Full Text] [Related]
58. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
59. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
60. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
